Design Therapeutics (DSGN) Stock: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$14.63
-0.17 (-1.15%)
âŧ
5d:
-2.66%
30d:
-0.2%
90d:
+38.94%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DSGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DSGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $14.63, which is considered fair relative to its 30-day fair value range of $14.07 to $15.54.
Technical Outlook: Technically, DSGN is in a uptrend. The price is currently testing key support at $14.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DSGN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.00 (+41.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DSGN is in a uptrend. The price is currently testing key support at $14.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DSGN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.00 (+41.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$14.07 -
$15.54
Company Quality Score
40/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 14th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.9% below Wall St target ($21.00)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.07 -
$15.54
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$2.80
(19.1%)
Support & Resistance Levels
Support Level
$14.38
Resistance Level
$15.75
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.29
Wall Street Target
$21.00
(+41.9%)
Share & Embed Analysis
Last updated: September 11, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
